Bayer remains committed to supporting NHS with improved access to Sativex®

Bayer HealthCare announces it is pleased that the National Institute for Health and Care Excellence (NICE) clinical guideline for the management of Multiple Sclerosis (MS) in primary and secondary care (CG186) recognises the multi-faceted nature of the disease and the complex needs of people with MS. Bayer welcomes the recommendation that MS patients should have a single point of contact and a comprehensive annual review but are disappointed that the guideline did not recommend Sativex® as a treatment option for moderate to severe spasticity.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Cost effectiveness Industry News Central Nervous System Latest News multiple sclerosis oromucosal spray Sativex spasticity Source Type: news